Organon is a pharmaceutical company that was spun off from Merck in 2021. It focuses therapeutics in women’s health, biosimilars, and established brands. OGN is truly a diversified global ...

Organon (OGN) announced results from an analysis of the Phase 3 ADORING 3 open-label, long-term extension study evaluating VTAMA cream, 1% once daily in adults and children 2 years of age and ...

JERSEY CITY, N.J., March 08, 2025--Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced results from an analysis of the Phase 3 ADORING 3 open-label ...

JERSEY CITY, N.J. (AP) — JERSEY CITY, N.J. (AP) — Organon & Co. (OGN) on Thursday reported fourth-quarter net income of $109 million. On a per-share basis… ...

Barclays analyst Balaji Prasad lowered the firm’s price target on Organon (OGN) to $24 from $26 and keeps an Overweight rating on the shares. The shares rallied post the Q4 report, owing to ...